ebomi
Colour theme
Sign in
Insider · CIK 0001581754

Tananbaum James B.

CIK 0001581754 Name as filed on the most recent filing

Filed as Tananbaum James B. (33)

72 transaction lines · from 33 filings · filed 2013-10-16 to 2026-08-10 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

17 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-08-10 P, Open-market purchase Latigo Biotherapeutics, Inc.LTGO 2,520,000, acquired Open Form 4 filing 0001581754-26-000006
2026-01-08 P, Open-market purchase Alumis Inc.ALMS 2 lines 6,999,988, acquired Open Form 4 filing 0001104659-26-003016
2025-11-21 P, Open-market purchase Alumis Inc.ALMS 532,925, acquired Open Form 4 filing 0001104659-25-115950
2025-11-19 P, Open-market purchase Alumis Inc.ALMS 1,249,680, acquired Open Form 4 filing 0001104659-25-114266
2025-11-18 P, Open-market purchase Alumis Inc.ALMS 726,545, acquired Open Form 4 filing 0001104659-25-114266
2025-11-17 P, Open-market purchase Alumis Inc.ALMS 2 lines 1,118,500, acquired Open Form 4 filing 0001104659-25-114266
2025-05-06 P, Open-market purchase Alumis Inc.ALMS 86,800, acquired Open Form 4 filing 0001104659-25-045222
2025-05-02 P, Open-market purchase Alumis Inc.ALMS 115,500, acquired Open Form 4 filing 0001104659-25-045222
2024-07-01 P, Open-market purchase Alumis Inc.ALMS 2 lines 40,000,000, acquired Open Form 4 filing 0001104659-24-077875
2023-07-17 P, Open-market purchase Theseus Pharmaceuticals, Inc.THRX 2 lines 2,079,000, acquired Open Form 4 filing 0001209191-23-042720
2023-05-08 P, Open-market purchase Kinnate Biopharma Inc.KNTE 2 lines 4,984,000, acquired Open Form 4 filing 0001209191-23-028537
2023-04-05 P, Open-market purchase Pardes Biosciences, Inc.PRDS 1,160,928, acquired Open Form 4 filing 0001213900-23-028117
2023-04-05 P, Open-market purchase Pardes Biosciences, Inc.PRDS 1,160,928, acquired Open Form 4 filing 0001213900-23-028116
2022-12-29 P, Open-market purchase Theseus Pharmaceuticals, Inc.THRX 2 lines 2,500,000, acquired Open Form 4 filing 0001209191-23-000204
2022-12-01 P, Open-market purchase Pardes Biosciences, Inc.PRDS 541,807, acquired Open Form 4 filing 0001213900-22-077637
2021-12-22 P, Open-market purchase Pardes Biosciences, Inc.PRDS 3,250,000, acquired Open Form 4 filing 0001213900-21-067341
2021-02-19 P, Open-market purchase FS Development Corp. IIFSII 6,025,000, acquired Open Form 4 filing 0001213900-21-011174
2020-12-03 P, Open-market purchase Kinnate Biopharma Inc.KNTE 3 lines 20,000,000, acquired Open Form 4 filing 0001140361-20-027407
2020-08-14 P, Open-market purchase FS Development Corp.FSDC 4,415,000, acquired Open Form 4 filing 0001213900-20-032139
2020-05-13 S, Open-market sale 10x Genomics, Inc.TXG 2 lines 116,188,500, disposed Open Form 4 filing 0000899243-20-013113
2020-03-17 S, Open-market sale 10x Genomics, Inc.TXG 2 lines 44,250,000, disposed Open Form 4 filing 0000899243-20-009021
2020-02-27 S, Open-market sale Aerie Pharmaceuticals IncAERI 3 lines 17,070,000, disposed Open Form 4 filing 0001209191-20-014562
2019-09-12 P, Open-market purchase 10x Genomics, Inc.TXG 7,312,500, acquired Open Form 4 filing 0001209191-19-049680
2019-09-05 P, Open-market purchase Aerie Pharmaceuticals IncAERI 289,194, acquired Open Form 4 filing 0001209191-19-048830
2019-09-04 P, Open-market purchase Aerie Pharmaceuticals IncAERI 2 lines 1,851,696, acquired Open Form 4 filing 0001209191-19-048830
2019-09-03 P, Open-market purchase Aerie Pharmaceuticals IncAERI 2 lines 1,040,741, acquired Open Form 4 filing 0001209191-19-048394
2019-08-30 P, Open-market purchase Aerie Pharmaceuticals IncAERI 534,000, acquired Open Form 4 filing 0001209191-19-048394
2019-08-23 P, Open-market purchase Aerie Pharmaceuticals IncAERI 896,986, acquired Open Form 4 filing 0001209191-19-047387
2019-08-22 P, Open-market purchase Aerie Pharmaceuticals IncAERI 158,656, acquired Open Form 4 filing 0001209191-19-047387
2019-08-21 P, Open-market purchase Aerie Pharmaceuticals IncAERI 26,807, acquired Open Form 4 filing 0001209191-19-047387
2019-08-20 P, Open-market purchase Aerie Pharmaceuticals IncAERI 1,160,500, acquired Open Form 4 filing 0001209191-19-046913
2019-08-19 P, Open-market purchase Aerie Pharmaceuticals IncAERI 89,789, acquired Open Form 4 filing 0001209191-19-046913
2019-08-16 P, Open-market purchase Aerie Pharmaceuticals IncAERI 2,423,000, acquired Open Form 4 filing 0001209191-19-046913
2019-08-14 P, Open-market purchase Aerie Pharmaceuticals IncAERI 2,373,000, acquired Open Form 4 filing 0001209191-19-046012
2019-08-13 P, Open-market purchase Aerie Pharmaceuticals IncAERI 2 lines 6,337,342, acquired Open Form 4 filing 0001209191-19-046012

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 17
  • Open-market sale 0
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Tananbaum James B., insider transactions. Retrieved 2026-08-26 from https://ebomi.com/insider/0001581754

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.